secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001437749-25-005951
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar appoints Quan Vu as CFO, replacing Karthik Radhakrishnan
----------------------------------------------------------------

- Karthik Radhakrishnan's employment terminated Feb 28, 2025; he ceased serving as CFO, principal financial and accounting officer.
- Quan Vu appointed CFO, principal accounting and financial officer effective March 3, 2025.
- Vu brings over 20 years of experience, most recently as Venture Partner at ZhongMei Capital, previously CFO/COO at Ocugen and 180 Life Sciences.
- Vu receives annual salary $350,000, target bonus up to 35% of base salary, and stock options for 25,000 shares vesting over 4 years.
- Options granted under Monopar's 2016 Stock Incentive Plan; no related party transactions reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925005951/0001437749-25-005951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925005951/mnpr20250228_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-005951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer